Thousands of complaints and lab records in 'bags of scrap': FDA inspects Cipla site in India
Another manufacturing site belonging to Cipla is under the FDA’s microscope.
An FDA inspection of one of Cipla’s manufacturing sites in Pithampur, India unveiled several quality and data observations between Feb.6 and Feb. 23 of this year. According to the 483 report, the manufacturing site received over 3,000 complaints between 2020 and 2022. The FDA’s report also stated that 266 complaints were also received this year and are still under investigation.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters